<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075188</url>
  </required_header>
  <id_info>
    <org_study_id>PDT Aflibercept</org_study_id>
    <nct_id>NCT04075188</nct_id>
  </id_info>
  <brief_title>Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid</brief_title>
  <official_title>Polypoidal Choroidal Vasculopathy in Pachychoroid: Aflibercept + PDT Combined Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate patients with diagnosis of polypoidal choroidal vasculopathy (PCV)
      in pachychoroid treated with combined therapy, consisting in photodynamic therapy (PDT) and 3
      intravitreal therapy (IVT) of Aflibercept monthly. This is a single center, prospective
      case-series study. The investigators are going to evaluate Corrected Distance Visual Acuity
      (CDVA), disease activity, retinal and choroidal thicknesses and number of injection per year,
      during a twelve month follow up. The aim of this study is to verify if the combined therapy
      can act on the insult induced by the pachychoroid and on the neovascular lesion itself in
      this sub-population of patients with PCV in pachychoroid,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates patients with diagnosis of polypoidal choroidal vasculopathy (PCV) in
      pachychoroid treated with combined therapy, consisting in photodynamic therapy (PDT) and 3
      intravitreal therapy (IVT) of Aflibercept monthly. Inclusion criteria are the presence of
      haemorrhagic or exudative PCV diagnosed by Optical Coherence Tomography (OCT) and Indocyanine
      Green Angiography (ICGA) and the mean central choroidal thickness &gt; 250 µm. Exclusion
      criteria comprehend ocular comorbidity, previous cardiovascular events and different ocular
      surgical procedures form cataract surgery. Participants undergo a thorough ophthalmic
      assessment that included best corrected visual acuity (CDVA), slit lamp biomicroscopy and
      dilated funduscopic examination. OCT, OCT-Angiography (OCT-A), ICGA and Fluoresceine
      Angiography (FA) were performed for all patients. The 12-month follow-up foresee monthly
      revaluations of the above measurements, excluding FA, repeated only on clinical judgement.
      CDVA will be measured using LogMAR. Choroidal and retinal thicknesses will be automatically
      measured by digital software OCT- integrated (IMAGEnet). All patients will be treated with a
      loading dose of Aflibercept combined with PDT within the first 7 days of the first
      intravitreal therapy. The spot size is calculated by adding 1000 μm to the greater linear
      dimension of the lesion. No additional therapy will be performed during follow-up unless
      signs of reactivation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Actual">July 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Selected patients with both diagnosis of polypoidal choroidal vasculoparthy and pachychoroid will be treated with combined therapy consisting in photodynamic therapy and 3 intravitreal therapy of Aflibercept monthly</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected Distance Visual Acuity</measure>
    <time_frame>twelve months</time_frame>
    <description>measured in logMAR notation using Early Treatment of Diabetic Retinopathy Study charts (CC-100XP LCD System for ETDRS Chart display)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Activity</measure>
    <time_frame>twelve months</time_frame>
    <description>measured as percentage of patients with subretinal or intraretinal fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>twelve months</time_frame>
    <description>Central retinal thickness (1 mm central foveal thickness) and mean macular thickness (second and the third 6-mm grid including parafoveal and perifoveal macular area)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Choroidal thickness</measure>
    <time_frame>twelve months</time_frame>
    <description>Central choroidal thickness (1 mm central subfoveal thickness) and mean choroideal thickness (second and the third 6-mm grid including parafoveal and perifoveal choroidal area)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of injections per year</measure>
    <time_frame>twelve months</time_frame>
    <description>Number of intravitreal injection administered in a year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <condition>Choroid Disease</condition>
  <arm_group>
    <arm_group_label>Combined therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept Injection</intervention_name>
    <description>Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.</description>
    <arm_group_label>Combined therapy</arm_group_label>
    <other_name>verteporfin for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of haemorrhagic or exudative PCV diagnosed by OCT and ICGA

          -  Mean central choroidal thickness &gt; 250 µm

        Exclusion Criteria:

          -  ocular comorbidity

          -  previous cardiovascular events

          -  different ocular surgical procedures form cataract surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Cillino, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOUP Paolo Giaccone, Palermo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2005 May;89(5):602-7.</citation>
    <PMID>15834093</PMID>
  </reference>
  <reference>
    <citation>Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK; EVEREST II study group. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017 Nov 1;135(11):1206-1213. doi: 10.1001/jamaophthalmol.2017.4030.</citation>
    <PMID>28983556</PMID>
  </reference>
  <reference>
    <citation>Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, Gemmy Cheung CM, Zhang Z, Leal S, Ishibashi T; PLANET Investigators. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. Am J Ophthalmol. 2019 Aug;204:80-89. doi: 10.1016/j.ajo.2019.02.027. Epub 2019 Mar 6.</citation>
    <PMID>30849345</PMID>
  </reference>
  <reference>
    <citation>Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015 Jan;35(1):1-9. doi: 10.1097/IAE.0000000000000331.</citation>
    <PMID>25158945</PMID>
  </reference>
  <reference>
    <citation>Balaratnasingam C, Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB. Polypoidal Choroidal Vasculopathy: A Distinct Disease or Manifestation of Many? Retina. 2016 Jan;36(1):1-8. doi: 10.1097/IAE.0000000000000774.</citation>
    <PMID>26414957</PMID>
  </reference>
  <reference>
    <citation>Yanagi Y, Ting DSW, Ng WY, Lee SY, Mathur R, Chan CM, Yeo I, Wong TY, Cheung GCM. CHOROIDAL VASCULAR HYPERPERMEABILITY AS A PREDICTOR OF TREATMENT RESPONSE FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina. 2018 Aug;38(8):1509-1517. doi: 10.1097/IAE.0000000000001758.</citation>
    <PMID>28704255</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</investigator_affiliation>
    <investigator_full_name>Salvatore Cillino</investigator_full_name>
    <investigator_title>Head of the Ophthalmology Section of the Department of Biomedicine, Neurosciences and Advanced Diagnostic</investigator_title>
  </responsible_party>
  <keyword>pachychoroid</keyword>
  <keyword>polypoidal choroidal vasculopathy</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>photodynamic therapy</keyword>
  <keyword>Swept source OCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Choroid Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

